Amin, S. http://orcid.org/0000-0002-2688-2529
Ruban-Fell, B.
Newell, I.
Evans, J.
Vyas, K.
Nortvedt, C.
Chin, R. F.
Funding for this research was provided by:
GW Pharmaceuticals (GW Pharmaceuticals)
Article History
Received: 23 February 2022
Accepted: 13 December 2023
First Online: 26 February 2024
Declarations
:
: Not applicable to this manuscript.
: Not applicable to this manuscript.
: This study was funded by GW Global Services (International) Ltd. Editorial and medical writing services were provided by Costello Medical. S. Amin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd; Medtronic Limited, Boston Scientific, Novartis, PTC therapeutics and Desitin; I. Newell, employee of Costello Medical; B. Ruban-Fell, employee of Costello Medical; J. Evans, employee of Costello Medical; K. Vyas, employee of GW Global Services (International) Ltd; C. Nortvedt, employee of GW Global Services (International) Ltd; R.F.M. Chin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd, Eisai, Zogenix, Neopharm Group and The Rize Medical Cannabis and Life Sciences UCITS ETF.